License and Collaboration Agreements - Additional Information (Details) - Collaborative Arrangement [Member] - SIIPL [Member]	1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 31, 2022 Product	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement date	2022-03
Initial license agreement for number of products | Product	3
Option to increase license agreement for number of products | Product	2
Option to purchase developed research plan and clinical trial data for percentage of actual cost	50.00%
Upfront license fee to be received		$ 5,000,000.0	$ 5,000,000.0
Collaborative arrangement aggregate milestone receivable		17,000,000.0	17,000,000.0
Maximum manufacturing technology transfer payments to be received		10,000,000.0	10,000,000.0
Receivable		10,000,000.0	10,000,000.0
Manufacturing technology transfer payment to be fully constrained		5,000,000.0	5,000,000.0
Billed remaining amount recorded as deferred revenue		$ 1,700,000	$ 1,700,000